T1	p 93 102	treatment
T2	p 325 370	of 95 patients with atherosclerotic disease .
T3	p 1985 1997	patients who
T4	i 58 70	lipid esters
T5	i 78 140	lipid-lowering treatment with diet , clofibrate and niceritrol
T6	i 187 197	clofibrate
T7	i 209 221	niceritrol .
T8	i 263 275	lipid esters
T9	i 419 423	diet
T10	i 478 504	clofibrate or niceritrol ,
T11	i 507 529	nicotinic acid ester ,
T12	i 632 664	treatment with diet , clofibrate
T13	i 669 679	niceritrol
T14	i 772 784	lipid esters
T15	i 942 979	monounsaturated fatty acids secreased
T16	i 988 1015	polyunsaturated fatty acids
T17	i 1079 1100	saturated fatty acids
T18	i 1134 1140	esters
T19	i 1145 1158	triglycerides
T20	i 1268 1295	clofibrate while niceritrol
T21	i 1360 1370	Clofibrate
T22	i 1418 1445	monounsaturated fatty acids
T23	i 1498 1504	esters
T24	i 1597 1607	linoleic (
T25	i 1646 1652	esters
T26	i 1732 1744	lipid esters
T27	i 1852 1867	saturated fatty
T28	i 1961 1981	clofibrate treatment
T29	i 2007 2046	diet enriched with polyunsaturated fats
T30	i 2099 2126	monounsaturated fatty acids
T31	i 2147 2153	esters
T32	i 2226 2249	saturated fatty acids .
T33	i 2283 2293	clofibrate
T34	o 27 43	acid composition
T35	o 58 70	lipid esters
T36	o 141 142	.
T37	o 160 183	proportion of linoleate
T38	o 232 248	acid composition
T39	o 694 730	significant serum lipid reductions .
T40	o 741 757	acid composition
T41	o 772 784	lipid esters
T42	o 849 855	degree
T43	o 859 876	dietary adherence
T44	o 964 979	acids secreased
T45	o 1045 1050	ratio
T46	o 1089 1114	fatty acids ( P/S ratio )
T47	o 1134 1160	esters and triglycerides .
T48	o 1498 1538	esters , triglycerides and phospholipids
T49	o 1597 1605	linoleic
T50	o 1646 1672	esters and triglycerides .
T51	o 1689 1696	1 ratio
T52	o 1770 1779	P/S ratio
T53	o 1868 1873	acids